Clinical Trials in Rheumatology in Ahmedabad
Dr. Dhaiwat Shukla has actively participated in multiple national and international clinical trials in the field of rheumatology and autoimmune diseases. His experience includes working as Principal Investigator, Co-Investigator, and Study Physician in research studies related to Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Osteoporosis, Ankylosing Spondylitis, Systemic Sclerosis, and other immune-mediated disorders. These studies help bring innovative and evidence-based treatments closer to patients while contributing to advancements in rheumatology care.
| Trial indication | Role | Drug | CTRI No |
|---|---|---|---|
| SLE(Minor organ) | Co Investigator | Cenerimod | CTRI/2025/07/090130 |
| SLE minor organ | Co Investigator | BRAVE study Baricitinib phase 3 | CTRI/2019/04/018378 |
| Systemic Sclerosis | Principal Investigator | Anifrolumab | CTRI/2022/02/040015 |
| Osteoporosis | Principal Investigator | Teriparatide | CTRI/2021/04/032769 |
| Osteoporosis | Principal Investigator | Denosumab | CTRI/2021/09/036190 |
| Osteoporosis | Principal Investigator | Teriparatide | CTRI/2023/08/056205 |
| SLE with Lupus Nephritis | Principal Investigator | Anifrolumab | CTRI/2022/02/040015 |
| Ankylosing Spondylitis | Principal Investigator | Adalimumab | CTRI/2023/11/059396 |
| Psoriatic Arthritis | Principal Investigator | Ixekizumab | CTRI/2023/06/053776 |
| Psoriatic arthritis | Co Investigator | Apremilast Phase 4 | CTRI/2019/01/017122 |
| Rheumatoid Arthritis | Principal Investigator | Adalimumab | CTRI/2023/11/059396 |
| Diabetes mellitus | Co Investigator | Orforglipron | CTRI/2023/10/058480 |
| Diabetes Mellitus type-2 | Principal Investigator | Deglusterol | CTRI/2023/07/054724 |
| Diabetes Mellitus type 2 | Co Investigator | Thymoquinone | CTRI/2021/08/036060 |
| Diabetes mellitus type II | Principal Investigator | Retatrutide | CTRI/2023/10/058324 |
| Diabetes Mellitus type II | Principal Investigator | Dulaglutide | CTRI/2022/12/048337 |
| HIV | Principal Investigator | HRF-10071 | CTRI/2022/02/040532 |
| HIV | Principal Investigator | HRF-10071 | CTRI/2022/12/048577 |
| Rabies | Co Investigator | Vaccine/Anti Rabies Immunoglobulin | CTRI/2019/06/019622 |
| Dengue | Co Investigator | Dengue mAb | CTRI/2021/07/035290 |
| COVID 19(Vaccine) | Principal Investigator | m-RNA vaccine as a booster | CTRI/2022/10/046475 |
| COVID-19 | Principal Investigator | Guduchyadi/Tinos pora Cordifolia | CTRI/2022/07/044204 |
| COVID 19 | Principal Investigator | Molnupiravir | CTRI/2021/07/034588 |
| COVID 19 | Co Investigator | Ashwagandha | CTRI/2020/05/025332 |
| COVID 19 | Co Investigator | Inosine Phase 3 | CTRI/2021/02/030892 |
| Diabetes | Co Investigator | Thymoquinone Phase 2/3 | CTRI/2021/08/036060 |
| COVID 19 | Principal Investigator | Thymoquinone Phase 2/3 | CTRI/2020/05/025167 |
| Chronic Constipation | Principal Investigator | Linaclotide | CTRI/2023/05/052685 |
| Post Operative Pain | Co Investigator | Paracetamol | CTRI/2023/05/052794 |